Which Wegovy dose actually starts weight loss?

The myth worth correcting: 0.25 mg is not the dose that drives weight loss

The most persistent misunderstanding about Wegovy is that people expect to start losing weight immediately at 0.25 mg, then wonder whether the medicine is working. It is working, just not yet in the way the package suggests. The 0.25 mg weekly dose exists for one reason: to introduce semaglutide to your system gradually, reducing the nausea, vomiting and reflux that can hit hard when a GLP-1 medicine is introduced at full strength. The NHS medicines page for semaglutide describes this starting phase clearly — it is a tolerability measure, not a therapeutic target.

Most people begin to notice genuine appetite suppression somewhere between the 0.5 mg and 1.0 mg stages. The signal is unmistakable: meals that used to disappear easily start leaving you satisfied halfway through. That shift is when the GLP-1 mechanism (slowing gastric emptying and signalling fullness to the brain) is starting to land. Some find it earlier; some find it clicks at 1.7 mg. The pace varies between individuals, which is exactly why a prescriber, not a pamphlet, steers the titration.

If you want to understand what the research shows at each specific level, the data on Wegovy weight loss by dose breaks down the clinical picture stage by stage. The short version: meaningful, sustained weight loss is almost always a 2.4 mg story, with the earlier doses as the necessary runway.

What the licensed dose schedule actually looks like

The standard Wegovy titration moves in roughly four-week steps: 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg as the maintenance dose. Your prescriber directs each step; if you tolerate a level well, the increase proceeds; if side effects are significant, the schedule can be paused. A full breakdown of the Wegovy dose steps sets out how each stage relates to the next.

In April 2026, the MHRA approved a dedicated 7.2 mg single-dose pen for adults with a BMI of 30 or above, titrated up from the same 0.25 mg starting point. Early trial data at that dose reported average weight loss of around 20.7% over 72 weeks, putting it closer to tirzepatide's results. The titration schedule to reach 7.2 mg is longer, and whether this dose is appropriate for you is a clinical conversation, not a self-selection. You can read more about the results at the 2.4 mg level to benchmark what the standard maintenance dose typically delivers before considering whether the higher pen is relevant for you.

One practical note: your pen arrives in plain, unbranded packaging via tracked DPD delivery, refrigerated and ready. The pen format changes as your dose increases, so the device you open at 0.5 mg looks different from the one at 2.4 mg. The Patient Information Leaflet inside each box covers storage and technique for that specific strength.

Why weight loss builds rather than arrives all at once

Semaglutide's effect on appetite is dose-dependent. The higher the dose, the stronger the GLP-1 receptor activation, the more pronounced the reduction in hunger, and the greater the caloric deficit that accumulates over weeks. The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults over 68 weeks on 2.4 mg semaglutide alongside lifestyle support. Average weight reduction was around 15%. That figure reflects the full treatment course, not just the first pen.

This matters because the 0.25 mg and 0.5 mg phases, while largely about tolerance, are also building the metabolic environment where the higher doses do their work. Stopping early because the first few weeks felt underwhelming is one of the more common reasons people miss out on results. The 1 mg stage is often where appetite suppression becomes noticeable enough to affect eating behaviour day to day, and the 0.5 mg phase is when most people get a first sense of the medicine's character.

A question our prescribers hear regularly: "Should I stay at a lower dose to avoid side effects?" The answer is clinical and individual. Staying below maintenance dose long-term is not recommended without clinical reason, the evidence base for sustained weight loss is built at 2.4 mg. If side effects are the concern, the titration pace can be adjusted. That is a conversation to have openly with whoever is prescribing for you.

Cost, access and what to check before starting

Understanding the dose ladder also helps make sense of treatment costs. Private Wegovy is priced per pen, and lower doses are typically less expensive than the higher maintenance pens. That can make the early weeks feel affordable in isolation, but the cost picture over a full titration is worth reviewing honestly before you begin. The Wegovy cost page sets out how pricing typically works across the dose range.

On the NHS, access to Wegovy is governed by NICE guidance (TA875), which recommends semaglutide for up to two years within a specialist weight management service for adults meeting specific BMI and comorbidity criteria. Waiting lists for those services can be long. Private treatment through a regulated online pharmacy is the practical alternative for people who meet the licensed criteria but cannot wait. The licensed eligibility is adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, such as hypertension or type 2 diabetes. BMI alone does not confirm suitability; a prescriber weighs the full picture.

If you are exploring whether semaglutide is the right choice or are weighing it against other licensed options, our treatment overview covers what is available. Our clinical team reviews every consultation personally. When you are ready to take that step, you can speak to our prescribers through a free consultation, no waiting list, reviewed the same day by a GPhC-registered prescriber.